Biotech Values

[dewophile]

This is in line w the JNJ data from a pretty large phase 2 that showed 80 percent efficacy for severe disease and 70 for milder lower respiratory tract disease.
Gsk never gave a point estimate except to say their data is “exceptional”. I don’t know if it’s still exceptional in light of the PFE data